191 citations · 279 across the 7 of their papers we have counts for
8 papers
TITE-CLRM: Towards efficient time-to-event dose-escalation guidance of multi-cycle cancer therapies
Lukas Andreas Widmer, Sebastian Weber, Yunnan Xu +1
Treatment of cancer has rapidly evolved over time in quite dramatic ways, for example from chemotherapies, targeted therapies to immunotherapies and chimeric antigen receptor T-cel…
Principled Drug-Drug Interaction Terms for Bayesian Logistic Regression Models of Drug Safety in Oncology Phase I Combination Trials
Lukas A. Widmer, Andrew Bean, David Ohlssen +1
In Oncology, trials evaluating drug combinations are becoming more common. While combination therapies bring the potential for greater efficacy, they also create unique challenges…
On weakly informative prior distributions for the heterogeneity parameter in Bayesian random-effects meta-analysis
Christian Röver, Ralf Bender, Sofia Dias +5
The normal-normal hierarchical model (NNHM) constitutes a simple and widely used framework for meta-analysis. In the common case of only few studies contributing to the meta-analys…
A Bayesian time-to-event pharmacokinetic model for phase I dose-escalation trials with multiple schedules
Burak Kürsad Günhan, Sebastian Weber, Tim Friede
Phase I dose-escalation trials must be guided by a safety model in order to avoid exposing patients to unacceptably high risk of toxicities. Traditionally, these trials are based o…
Predictively Consistent Prior Effective Sample Sizes
Beat Neuenschwander, Sebastian Weber, Heinz Schmidli +1
Determining the sample size of an experiment can be challenging, even more so when incorporating external information via a prior distribution. Such information is increasingly use…
Applying Meta-Analytic-Predictive Priors with the R Bayesian evidence synthesis tools
Sebastian Weber, Yue Li, John Seaman +2
Use of historical data in clinical trial design and analysis has shown various advantages such as reduction of within-study placebo-treated number of subjects and increase of study…